Severe inflammatory ophthalmopathy in a euthyroid patient during nivolumab treatment

European Thyroid Journal

Volumn 7, Issue 2, 2018, Pages 84-87

  Campredon, Pauline ^a   Imbert, Philippe ^a,b   Mouly, Céline ^a   Grunenwald, Solange ^a   Mazières, Julien ^a   Caron, Philippe ^a  

^a SERVICE DE PNEUMOLOGIE   (France)

^b Clinique du Parc   (France)

Author keywords

Cigarette smoking; Nivolumab; Non small cell lung cancer; Ophthalmopathy; Pathogenesis

Indexed keywords

METHYLPREDNISOLONE; NIVOLUMAB;

ADULT; ARTICLE; CASE REPORT; CHEMOSIS; CLINICAL ARTICLE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOGRAPHY; EUTHYROIDISM; EXTRAOCULAR MUSCLE; EYE DISEASE; EYE REDNESS; HEMOPTYSIS; HUMAN; INFLAMMATORY OPHTHALMOPATHY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOPLEGIA; PRIORITY JOURNAL; PTOSIS; X-RAY COMPUTED TOMOGRAPHY;

EID: 85051276165     PISSN: 22350640     EISSN: 22350802     Source Type: Journal    
DOI: 10.1159/000485742     Document Type: Article

References (11)

1. Barbee MS, Ogunniyi A, Horvat TZ, Dang TO: Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother 2015; 49: 907-937.
2. Philips GK, Atkins M: Therapeutic uses of anti-PD-1 and anti-PD-LI antibodies. Int Immunol 2015; 27: 39-46.
3. Abdel-Rahman O, Oweira H, Tetrausch U, Helbling D, Schmidt J, Mannhart M, Mehrabi A, Schöb O, Giryes A: Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: A systematic review. Expert Rev Anticancer Ther 2017; 17: 387-394.
4. Lecouflet M, Verschoore M, Giard C, Gohier P, Le Corre Y, Milea D, Martin L: Orbital myositis associated with ipilimumab. Ann Dermatol Venereol 2013; 140: 448-451.
5. Min L, Vaidya A, Becker C: Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 2011; 164: 303-307.
6. Borodic G, Hinkle DM, Cia Y: Drug-induced Graves disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg 2011; 27:e87-e88.
7. McElnea E, Ní Mheáloíd A, Moran S, Kelly R, Fulcher T: Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab. Orbit 2014; 33: 424-427.
8. Sohrab MA, Desai RU, Chambers CB, Lissner GS: Re: "Drug-induced Graves disease from CTLA-4 receptor suppression." Ophthal Plast Reconstr Surg 2013; 29: 239-240.
9. Khoo DH, Eng PH, HO SC, Tai ES, Morgenthaler NG, Seah LL, Fong KS, Chee SP, Choo CT, Aw SE: Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: Prevalence, natural history, and thyrotropin receptor antibody levels. Thyroid 2000; 10: 1093-1100.
10. Borodic GE, Hinkle D: Ipilimumab-induced orbital inflammation resembling Graves disease with subsequent development of systemic hyperthyroidism from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg 2014; 30: 83.
11. Borodic GE, Hinkle DM: Reply Re: "Druginduced Graves disease from CTLA-4 receptor suppression." Ophthal Plast Reconstr Surg 2013; 29: 241.